Australia Recognises Bharat Biotech’s Covaxin

November 01

Australia Supports Covaxin

Australia recognised Bharat Biotech’s Vaccine against Covid-19 ‘Covaxin’ on Monday. With this, now travelers who have  received this vaccine, shall be allowed for entry into Australia.

The Therapeutic Goods Administration (TGA), the Australian drug regulator, announced that it has recognised two more Covid-19 vaccines not registered in Australia but used widely internationally, which includes Bharat Biotech’s Covaxin and BBIBP-CorV (manufactured by Sinopharm, China).

TGA has given this recognition for travelers aged 12 and over who have been vaccinated with Covaxin and those 18 to 60 who have been vaccinated with BBIBP-CorV.

Australian Technical Advisory Group on Immunisation (ATAGI) (ATAGI) have determined that those who have received two doses of a TGA-approved or recognised vaccine at least 14 days apart are regarded as fully vaccinated from seven days after the second dose (with the exception of Janssen vaccine, where they are regarded as fully vaccinated seven days after the single dose).

This includes homologous (two doses of the same vaccine) and heterologous (two doses of two different TGA-approved or recognised vaccines) schedules.